Evidence map›Paper›PMID 41078577›Full record

ArticleMolecular genetics and metabolism reports2025

Molecular characterization of a novel synonymous variant in a Mexican patient with Pompe disease.

Carmen Alaez-Verson, Carlos Alberto González-Domínguez, Imelda Vergara Sanchez, Luz María Sanchez Sanchez, Ivonne Natalia Flores, Ekaterina Kazakova, Joaquin Garcia-Solorio, Carolina Molina-Garay, Luis Leonardo Flores-Lagunes, Ivan Martínez Duncker

Abstract read
In one paragraph

Article in Molecular genetics and metabolism reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carmen Alaez-VersonLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Carlos Alberto González-DomínguezLaboratorio de Glicobiologia Humana y Diagnóstico Molecular, Centro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Morelos, Mexico.
Imelda Vergara SanchezServicio de Neurología pediátrica, Hospital de Alta Especialidad del CMN "Ignacio Garcia Tellez", Instituto Mexicano del Seguro Social, Merida, Mexico.
Luz María Sanchez SanchezDepartamento de pediatría unidad médica de alta especialidad 25 (UMAE 25), Centro Médico Nacional del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico.
Ivonne Natalia FloresMedical Manager for Rare Diseases at Sanofi Pasteur Specialty Care, Mexico City, Mexico.
Ekaterina KazakovaMedical Manager for Rare Diseases at Sanofi Pasteur Specialty Care, Mexico City, Mexico.
Joaquin Garcia-SolorioLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Carolina Molina-GarayLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Luis Leonardo Flores-LagunesLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Ivan Martínez DunckerLaboratorio de Glicobiologia Humana y Diagnóstico Molecular, Centro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Morelos, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pompe disease (PD) is an autosomal recessive disorder caused by a deficiency of lysosomal acid alpha-1,4-glucosidase (GAA; EC 3.2.1.20), encoded by the GAA gene, leading to progressive neuromuscular deterioration. The mutational spectrum of Methods: DNA and RNA were extracted from peripheral blood. Next-generation sequencing of a clinical exome panel identified variants in the Results: The pathogenic variant c.1979G > A (p.Arg660His) and a novel VUS c.2799G > A (p.Lys933=) were detected. The variant c.2799G > A is predicted to affect splicing. mRNA analysis revealed three isoforms, one corresponding to c.1979G > A and two others caused by alternative splicing of c.2799G > A (isoforms 1 and 2). The isoform-1 showed c.2799G > A, followed by 61 bp retention of intron 19, predicted to cause a frameshift p.(A934fs). Isoform 2 has a 90 bp deletion in exon 19, resulting in a p.V904_K933del in-frame deletion. Discussion: This study demonstrates that the synonymous variant c.2799G > A is pathogenic due to its impact on RNA splicing. Our findings highlight the importance of transcript analysis for VUS reclassification and stress the clinical relevance of evaluating synonymous variants in genetic diagnostics and patient management.

Indexed as

Alpha-glucosidase deficiencyGAA geneInfantile-onset Pompe diseaseMexican patientP.(Lys933=) variantPompe disease

Identifiers

PMID41078577
PMCPMC12510008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.